Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
J. Clin. Invest. Vinayakumar Siragam, et al. 115:155 doi:10.1172/JCI22753 [Go to this article.]

Figure 2
Pretreatment of mice with OVA-rbcs + anti-OVA ameliorates ITP. CD1 mice were injected intravenously with 10⁸ OVA-rbcs + anti-OVA or OVA-rbcs + control IgG, or OVA-rbcs or anti-OVA only, as indicated on the x axis. Mice were then treated as described in Figure 1. n = 9 mice for each group from 3 independent experiments. ^#P < 0.001 vs. ITP mice. Data are presented as mean ± SEM.